Rep. Lisa C. McClain Sells Novartis AG (NYSE:NVS) Shares

Representative Lisa C. McClain (R-Michigan) recently sold shares of Novartis AG (NYSE:NVS). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Novartis stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Novartis Stock Down 0.2%

Shares of NYSE:NVS traded down $0.22 during trading on Friday, reaching $130.23. The stock had a trading volume of 1,514,183 shares, compared to its average volume of 1,834,071. The firm’s 50-day simple moving average is $128.31 and its 200 day simple moving average is $122.51. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.50. Novartis AG has a one year low of $96.06 and a one year high of $134.00. The company has a market capitalization of $275.09 billion, a P/E ratio of 17.79, a PEG ratio of 1.93 and a beta of 0.60.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $2.25 EPS for the quarter, missing the consensus estimate of $2.26 by ($0.01). The business had revenue of $14.36 billion for the quarter, compared to analysts’ expectations of $13.70 billion. Novartis had a net margin of 26.49% and a return on equity of 41.21%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.06 EPS. As a group, research analysts expect that Novartis AG will post 8.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NVS has been the topic of a number of research reports. Morgan Stanley raised Novartis from an “equal weight” rating to an “overweight” rating in a report on Friday, October 31st. Cfra set a $126.00 price target on shares of Novartis and gave the stock a “hold” rating in a report on Wednesday, October 29th. Cowen restated a “hold” rating on shares of Novartis in a research note on Monday, November 10th. The Goldman Sachs Group reiterated a “sell” rating and issued a $118.00 price objective (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. Finally, Cfra Research upgraded Novartis to a “hold” rating in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $122.33.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Brighton Jones LLC boosted its position in Novartis by 76.5% during the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after acquiring an additional 2,666 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Novartis by 27.8% in the 1st quarter. Victory Capital Management Inc. now owns 123,030 shares of the company’s stock worth $13,715,000 after purchasing an additional 26,789 shares in the last quarter. IFP Advisors Inc boosted its holdings in shares of Novartis by 23.5% during the 1st quarter. IFP Advisors Inc now owns 2,137 shares of the company’s stock worth $238,000 after purchasing an additional 407 shares during the last quarter. J.W. Cole Advisors Inc. grew its position in shares of Novartis by 92.4% in the first quarter. J.W. Cole Advisors Inc. now owns 10,349 shares of the company’s stock valued at $1,154,000 after purchasing an additional 4,969 shares in the last quarter. Finally, Allianz Asset Management GmbH increased its holdings in shares of Novartis by 19.6% in the first quarter. Allianz Asset Management GmbH now owns 6,700 shares of the company’s stock valued at $747,000 after purchasing an additional 1,100 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.